Skip to Main Content

Facing pressing questions about its latest clinical trial in Alzheimer’s disease, Biogen may have sowed further doubt on the future of an investigational treatment on Thursday.

At a medical conference in Spain, Biogen and partner Eisai presented data on the drug, BAN2401, meant to clear up concerns that its earlier observed benefits were a mirage. But the explanation revealed that BAN2401’s glimmer of promise is based on results from a small subset of patients in an otherwise large trial, which could be difficult to replicate in later studies.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • This is typical of the “innovative” deceptive science they are all doing now. These truncated distorted studies, get the attention of industry “journalists” who are indistinguishable from marketers. A few Industry publications will hype these “findings’ and get plenty of funding, and even taxpayer dollars from our government agencies. Depending on where this is advertised, using deceptive marketing, advertorials, and misleading alternate facts, this will be profitable. It may waste billions of research dollars, but a few clever people will make a whole lot of money. They have been misleading us about all of the previous research, and kept getting government grants to “study” clearly useless drugs, because it was profitable. In the meantime real people have to deal with these disorders, day in and out. Most Americans will find that these disorders are misdiagnosed, and their families, livelihoods, and lives will be negatively impacted. The interventions are mostly lies, with most Physicians unable or unwilling to even diagnosed these disorders before lives are ruined.

Comments are closed.